TY - JOUR
T1 - Duration and extent of antianginal effects of a sustained-release formulation of nifedipine in angina
AU - Yokota, M.
AU - Saito, F.
AU - Izawa, H.
AU - Matsunami, T.
AU - Yoshida, J.
AU - Inagaki, H.
AU - Sotobata, I.
PY - 1994
Y1 - 1994
N2 - Twenty-four patients with chronic stable exertional angina pectoris were randomized in a double-blind, placebo-controlled, crossover trial to assess the efficacy and durability of a newly developed sustained-release formulation of nifedipine (nifedipine CC) in a single 40-mg oral dose. Symptom-limited graded treadmill exercise tests were performed just before and at 4, 7, and 24 h after a single administration of the drug or the placebo was given. Exercise tolerance at 4, 7, and 24 h after the drug were compared with the corresponding placebo values. Data could be analysed for 19 patients. Maximal exercise time time to the onset of angina and time to 1 mm ST segment depression were significantly greater at 4, 7, and 24 h after nifedipine CC than at baseline or with the corresponding placebo. The average maximal exercise time was significantly increased by 72, 76 and 37 s at 4, 7, and 24 h. Rate-pressure product at rest and at peak exercise showed significant changes only at 24 h compared with placebo (both P < 0.05). The maximal increase in exercise tolerance was most marked at 7 h after nifedipine CC at which time plasma drug concentration was 99.4 ± 14.0 ng.ml-1. Thus, in patients with chronic stable exertional angina pectoris nifedipine CC showed a prolonged improvement in exercise tolerance up to 24 h after a single oral administration.
AB - Twenty-four patients with chronic stable exertional angina pectoris were randomized in a double-blind, placebo-controlled, crossover trial to assess the efficacy and durability of a newly developed sustained-release formulation of nifedipine (nifedipine CC) in a single 40-mg oral dose. Symptom-limited graded treadmill exercise tests were performed just before and at 4, 7, and 24 h after a single administration of the drug or the placebo was given. Exercise tolerance at 4, 7, and 24 h after the drug were compared with the corresponding placebo values. Data could be analysed for 19 patients. Maximal exercise time time to the onset of angina and time to 1 mm ST segment depression were significantly greater at 4, 7, and 24 h after nifedipine CC than at baseline or with the corresponding placebo. The average maximal exercise time was significantly increased by 72, 76 and 37 s at 4, 7, and 24 h. Rate-pressure product at rest and at peak exercise showed significant changes only at 24 h compared with placebo (both P < 0.05). The maximal increase in exercise tolerance was most marked at 7 h after nifedipine CC at which time plasma drug concentration was 99.4 ± 14.0 ng.ml-1. Thus, in patients with chronic stable exertional angina pectoris nifedipine CC showed a prolonged improvement in exercise tolerance up to 24 h after a single oral administration.
UR - http://www.scopus.com/inward/record.url?scp=0028240873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028240873&partnerID=8YFLogxK
U2 - 10.1093/oxfordjournals.eurheartj.a060617
DO - 10.1093/oxfordjournals.eurheartj.a060617
M3 - Article
C2 - 7925519
AN - SCOPUS:0028240873
SN - 0195-668X
VL - 15
SP - 965
EP - 970
JO - European heart journal
JF - European heart journal
IS - 7
ER -